Short Interest in Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Decreases By 35.3%

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) was the target of a significant drop in short interest during the month of September. As of September 15th, there was short interest totaling 41,200 shares, a drop of 35.3% from the August 31st total of 63,700 shares. Based on an average daily volume of 54,500 shares, the days-to-cover ratio is presently 0.8 days. Approximately 1.0% of the company’s shares are short sold. Approximately 1.0% of the company’s shares are short sold. Based on an average daily volume of 54,500 shares, the days-to-cover ratio is presently 0.8 days.

Coeptis Therapeutics Stock Performance

COEP stock opened at $17.00 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 0.83 and a quick ratio of 0.83. The business has a 50-day moving average price of $13.28 and a 200 day moving average price of $10.67. The company has a market capitalization of $81.94 million, a P/E ratio of -2.93 and a beta of -0.49. Coeptis Therapeutics has a 1-year low of $2.31 and a 1-year high of $19.19.

Coeptis Therapeutics (NASDAQ:COEP) last released its quarterly earnings data on Thursday, August 14th. The company reported ($1.17) earnings per share for the quarter. The company had revenue of $0.20 million during the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Coeptis Therapeutics in a research report on Saturday, September 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.